Plain-English translation of NCT06898255 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called GFS202A designed to help people with advanced solid tumors who are experiencing cancer-related weight loss and appetite problems. Researchers want to understand how safe this treatment is, what side effects it might cause, and how the body processes it. The study will enroll about 36 participants and test different dose levels to find the right amount to use in future studies.
Cancer cachexia — severe weight loss and muscle wasting caused by cancer — is a serious problem that affects many patients with advanced tumors and can reduce quality of life. This medication is being tested to see if it can help patients maintain their weight and appetite, which may improve their overall health and well-being.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an outpatient, likely at multiple visits to the study center. During the trial, you would have regular check-ups including blood draws and other assessments to monitor your safety and how your body responds to the treatment. The study team will track your weight, appetite, and overall health, and may ask you to answer questions about how you are feeling. The exact number of visits and length of the trial will depend on which dose level you are assigned to, but the study is designed to last several weeks to months.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China